Cargando…

Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation

BACKGROUND: Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is characterized by high chemotherapy resistance; however, the underlying mechanism has not been fully clarified. In addition, HBx protein has been reported to play a key role in virus-mediated hepatocarcinogenesis. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanning, Lou, Guohua, Wu, Wei, Shi, Yu, Zheng, Min, Chen, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680016/
https://www.ncbi.nlm.nih.gov/pubmed/23718853
http://dx.doi.org/10.1186/1743-422X-10-168
_version_ 1782273058060369920
author Liu, Yanning
Lou, Guohua
Wu, Wei
Shi, Yu
Zheng, Min
Chen, Zhi
author_facet Liu, Yanning
Lou, Guohua
Wu, Wei
Shi, Yu
Zheng, Min
Chen, Zhi
author_sort Liu, Yanning
collection PubMed
description BACKGROUND: Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is characterized by high chemotherapy resistance; however, the underlying mechanism has not been fully clarified. In addition, HBx protein has been reported to play a key role in virus-mediated hepatocarcinogenesis. Therefore, the present study aims to investigate the role of HBx in the drug-resistance of HBV-related HCC and examine whether such drug-resistance can be reversed by IFN-α treatment. METHODS: We established HBx-expressing cells by liposome-mediated transfection of HBx into the Huh7 cell line. MTT, Annexin V/PI, and cell cycle assay were used for determining the cellular growth inhibition, apoptosis, and growth arrest, respectively, after treatment with chemical drug. We further used tumor-bearing mice model to compare the tumor growth inhibition efficacy of ADM and 5-FU between the Huh7-HBx group and the control group, as well as the ADM + IFN-α or ADM + IMD treated group and the ADM treated group. SQ-Real time-PCR was performed to analyze the expression of MDR-associated genes and anti-apoptotic genes. Moreover, immunofluorescence and Western blotting were used to determine the subcellular localization of p65 and the phosphorylation of IκBα. RESULTS: The IC(50) values of Huh7-HBx cells against ADM and Amn were 2.317 and 1.828-folds higher than those of Huh7-3.1 cells, respectively. The apoptosis ratio and growth arrest was significantly lower in Huh7-HBx cells after treatment with ADM. The in vivo experiment also confirmed that the Huh7-HBx group was much more resistant to ADM or 5-FU than the control. Furthermore, the expression of MDR-associated genes, such as MDR1, MRP1, LRP1, and ABCG2, were significantly up-regulated in Huh7-HBx cells, and the NF-κB pathway was activated after HBx gene transfection in Huh7 cells. However, combined with IFN-α in ADM treatment, the HBx induced drug-resistance in Huh7-HBx cells can be partly abolished in in vitro and in vivo models. Moreover, we found that the NF-κB canonical pathway was affected by IFN-α treatment, and the expression of anti-apoptotic genes, such as Gadd45β, Survivin, and c-IAP-1 was down-regulated by IFN-α treatment in a dose-dependent manner. CONCLUSIONS: HBx protein can induce MDR of HBV-related HCC by activating the NF-κB pathway, which can be partly abolished by IFN-α treatment.
format Online
Article
Text
id pubmed-3680016
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36800162013-06-13 Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation Liu, Yanning Lou, Guohua Wu, Wei Shi, Yu Zheng, Min Chen, Zhi Virol J Research BACKGROUND: Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is characterized by high chemotherapy resistance; however, the underlying mechanism has not been fully clarified. In addition, HBx protein has been reported to play a key role in virus-mediated hepatocarcinogenesis. Therefore, the present study aims to investigate the role of HBx in the drug-resistance of HBV-related HCC and examine whether such drug-resistance can be reversed by IFN-α treatment. METHODS: We established HBx-expressing cells by liposome-mediated transfection of HBx into the Huh7 cell line. MTT, Annexin V/PI, and cell cycle assay were used for determining the cellular growth inhibition, apoptosis, and growth arrest, respectively, after treatment with chemical drug. We further used tumor-bearing mice model to compare the tumor growth inhibition efficacy of ADM and 5-FU between the Huh7-HBx group and the control group, as well as the ADM + IFN-α or ADM + IMD treated group and the ADM treated group. SQ-Real time-PCR was performed to analyze the expression of MDR-associated genes and anti-apoptotic genes. Moreover, immunofluorescence and Western blotting were used to determine the subcellular localization of p65 and the phosphorylation of IκBα. RESULTS: The IC(50) values of Huh7-HBx cells against ADM and Amn were 2.317 and 1.828-folds higher than those of Huh7-3.1 cells, respectively. The apoptosis ratio and growth arrest was significantly lower in Huh7-HBx cells after treatment with ADM. The in vivo experiment also confirmed that the Huh7-HBx group was much more resistant to ADM or 5-FU than the control. Furthermore, the expression of MDR-associated genes, such as MDR1, MRP1, LRP1, and ABCG2, were significantly up-regulated in Huh7-HBx cells, and the NF-κB pathway was activated after HBx gene transfection in Huh7 cells. However, combined with IFN-α in ADM treatment, the HBx induced drug-resistance in Huh7-HBx cells can be partly abolished in in vitro and in vivo models. Moreover, we found that the NF-κB canonical pathway was affected by IFN-α treatment, and the expression of anti-apoptotic genes, such as Gadd45β, Survivin, and c-IAP-1 was down-regulated by IFN-α treatment in a dose-dependent manner. CONCLUSIONS: HBx protein can induce MDR of HBV-related HCC by activating the NF-κB pathway, which can be partly abolished by IFN-α treatment. BioMed Central 2013-05-29 /pmc/articles/PMC3680016/ /pubmed/23718853 http://dx.doi.org/10.1186/1743-422X-10-168 Text en Copyright © 2013 Liu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Liu, Yanning
Lou, Guohua
Wu, Wei
Shi, Yu
Zheng, Min
Chen, Zhi
Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title_full Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title_fullStr Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title_full_unstemmed Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title_short Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation
title_sort interferon-α sensitizes hbx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of hbx-mediated nf-κb activation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680016/
https://www.ncbi.nlm.nih.gov/pubmed/23718853
http://dx.doi.org/10.1186/1743-422X-10-168
work_keys_str_mv AT liuyanning interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation
AT louguohua interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation
AT wuwei interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation
AT shiyu interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation
AT zhengmin interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation
AT chenzhi interferonasensitizeshbxexpressinghepatocarcinomacellstochemotherapeuticdrugsthroughinhibitionofhbxmediatednfkbactivation